Agas RAF, et al. - In this retrospective review of 32 patients treated at the authors' institution, the oncologic outcomes and the treatment-related toxicities after reirradiation (re-RT) for recurrent nasopharyngeal carcinoma (rNPC) were assessed, and a recently published prognostic model for survival in rNPC was applied. The modalities used for re-RT included intensity-modulated radiotherapy (n=14), three-dimensional conformal radiotherapy (n=9), single-fraction stereotactic radiosurgery (n=6), fractionated stereotactic radiotherapy (n=2), and high dose rate intracavitary brachytherapy (n=1). re-RT with curative intent was administered to 27 patients, whereas 5 patients were treated palliatively. Median locoregional recurrence-free survival (LRRFS) of 14 months was reported for the overall cohort, with actuarial 1- and 2-year LRRFS estimates of 67.5% and 44.0%, respectively. They also reported median overall survival (OS) time of 38 months, with actuarial 1- and 2-year estimates of 74.2% and 57.2%, respectively. Overall, findings demonstrated safety as well as efficacy of re-RT as a salvage treatment strategy for rNPC. Good LRRFS and prolonged OS could be achieved with re-RT to a maximum equivalent dose in 2-Gy fractions of 60 Gy.